Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||ARID1A Y788* ARID1A M1154fs|
|Gene Variant Detail||
ARID1A M1154fs (loss of function - predicted)
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ARID1A Y788* ARID1A M1154fs||ovarian clear cell carcinoma||predicted - sensitive||Bevacizumab + Pembrolizumab||Case Reports/Case Series||Actionable||In a clinical case study, a patient with ovarian clear cell carcinoma harboring both ARID1A Y788* and M1154fs was sensitive to the combination therapy of Keytruda (pembrolizumab) and Avastin (bevacizumab), demonstrating a decrease in serum marker, tumor regression after 3 cycles, and complete remission after 9 cycles of treatment (PMID: 33292376).||33292376|